Skip to Content

Nucala Approval History

Nucala (mepolizumab) is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for the add-on maintenance treatment of patients with severe eosinophilic asthma, and for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).

Development History and FDA Approval Process for Nucala

DateArticle
Dec 12, 2017Approval FDA Approves Nucala (mepolizumab) for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome)
Nov  4, 2015Approval FDA Approves Nucala (mepolizumab) to Treat Severe Asthma
Jun 11, 2015GSK Announces Outcome of US FDA Advisory Committee Recommending Approval of Mepolizumab for Severe Asthma
Nov  5, 2014GSK Announces Regulatory Submissions for Mepolizumab in Severe Eosinophilic Asthma
Sep  8, 2014NEJM and ERS publish positive results from GSK phase III studies of mepolizumab
Mar 12, 2014GSK announces positive results from phase III studies for mepolizumab in severe eosinophilic asthma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide